Peptides News and Research

RSS

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy: injectable fluorescent peptides that cause hard-to-see peripheral nerves to glow, alerting surgeons to their location even before the nerves are encountered.

6 Feb 2011

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.

4 Feb 2011

MicroCHIPS commences first hPTH clinical study in women with osteoporosis

MicroCHIPS, a developer of innovative drug delivery systems, is initiating the first clinical study to demonstrate precisely controlled delivery of a peptide from a multi-reservoir, programmable, implant system.

4 Feb 2011

International scientist team identifies gene mutation strongly linked to schizophrenia

In a major advance for schizophrenia research, an international team of scientists, led by Jonathan Sebat, PhD, assistant professor of psychiatry and cellular and molecular medicine at the University of California, San Diego School of Medicine, has identified a gene mutation strongly linked to the brain disorder - and a signaling pathway that may be treatable with existing compounds.

3 Feb 2011

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

A targeted delivery combination selectively crosses the tight barrier that protects the brain from the bloodstream to home in on and bind to brain tumors, a research team led by scientists from The University of Texas MD Anderson Cancer Center reported in the January issue of the Journal of Clinical Investigation.

2 Feb 2011

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Zealand Pharma A/S, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, is pleased to announce that its partner, sanofi-aventis, today announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily.

2 Feb 2011

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Genzyme Corporation today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.

1 Feb 2011

Discovery Labs provides expanded update on efforts to gain FDA marketing authorization for Surfaxin in RDS

Discovery Laboratories, Inc. is providing an expanded update regarding ongoing efforts to file a Complete Response intended to gain U.S. Food and Drug Administration (FDA) marketing authorization for Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.

1 Feb 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

Venture philanthropist invests $3.5 million to thwart Alzheimer's disease

Retired San Francisco real estate developer Douglas Rosenberg says he has a new job - helping to find a cure for Alzheimer's disease. Through the Ellen and Douglas Rosenberg Foundation, the venture philanthropist is betting at least $3.5 million that Buck faculty Dale Bredesen, MD has the correct take on how to thwart the memory robbing disease that affects over 5 million Americans.

31 Jan 2011

Research shows nestin regulates formation of neuromuscular junction

In a study published in the Jan. 30, 2011, advance online edition of Nature Neuroscience, Salk Institute of Biological Studies investigators led by Kuo-Fen Lee, PhD., show that nestin has reason for being in a completely different cell type--muscle tissue.

30 Jan 2011

U-M researchers reveal molecular signals that regulate catch-up growth

University of Michigan researchers have uncovered molecular signals that regulate catch-up growth---the growth spurt that occurs when normal conditions are restored after a fetus, young animal or child has been ill, under stress or deprived of enough food or oxygen to grow properly.

29 Jan 2011

BioTime announces acquisition of CTI assets

BioTime, today announced that it has acquired substantially all the assets of Cell Targeting, a Cleveland, Ohio-based biotechnology company conducting research in regenerative medicine.

29 Jan 2011

Misaligned research, medical challenges and harsh economics thwart efforts against Alzheimer's disease

Misaligned research, medical challenges and harsh economics are thwarting efforts to slow the destructive course of Alzheimer's disease in the United States, according to a trio of nationally regarded Alzheimer's researchers writing a "Perspective" in Jan. 27 issue of the journal Neuron.

28 Jan 2011

Triggering CD45 molecule blocks early development of AD

A new target for the prevention of adverse immune responses identified as factors in the development of Alzheimer's disease (AD) has been discovered by researchers at the University of South Florida's Department of Psychiatry and the Center of Excellence for Aging and Brain Repair.

27 Jan 2011

MGH investigators develop novel system to deliver growth factors to chronic wounds

Massachusetts General Hospital investigators have developed a novel system for delivery of growth factors to chronic wounds such as pressure sores and diabetic foot ulcers.

27 Jan 2011

Simple means of improving binding affinity of synbodies

Antibodies are watchdogs of human health, continuously prowling the body and registering minute changes associated with infection or disease with astonishing acuity. They also serve as biochemical memory banks, faithfully recording information about pathogens they encounter and efficiently storing this data for later use.

25 Jan 2011

Eckert & Ziegler receives European Commission's indefinite approval for YTTRIGA

Eckert & Ziegler Strahlen- und Medizintechnik AG, a firm specializing in radioactive compounds for the treatment of cancer, has renewed the approval of its drug YTTRIGA (Yttrium-90 chloride) by the European Commission. Five years ago the European Medicines Agency EMA approved this drug for the first time and as a result of the current renewal process the drug has now been granted an indefinite approval.

24 Jan 2011

Odontoblast cells are part of immune system, protect teeth from decay: New research

It is known that teeth can protect themselves, to some extent, from attack by bacteria but that inflammation within a tooth can be damaging and, in extreme cases, lead to abscess or death of the tooth. New research published in BioMed Central's open access journal BMC Immunology shows that odontoblast cells are part of the immune system and fight to protect teeth from decay.

23 Jan 2011

Researchers map complex choreography used by immune system's T cells to recognize pathogens

Researchers have for the first time mapped the complex choreography used by the immune system's T cells to recognize pathogens while avoiding attacks on the body's own cells.

21 Jan 2011